Organon (OGN) ended the recent trading session at $9.70, demonstrating a -3.39% change from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.37%. Meanwhile, the Dow experienced a drop of 0.74%, and the technology-dominated Nasdaq saw a decrease of 0.03%. The stock of pharmaceutical company has fallen by 1.08% in the past month, lagging the Medical sector's loss of 0.88% and the S&P 500's gain of 2.68%.The investment community will be paying close attention ...

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Organon investors who were adversely affected by alleged securities fraud between October 31, 2024 and April 30, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/organon-co-lawsuit-submission-for ...

NEW YORK, July 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Organon investors who were adversely affected by alleged securities fraud between October 31, 2024 and April 30, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid ...

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN). Shareholders who purchased shares of OGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/organon-co-loss-submission-form/?id=157198&from=3 CLASS PERIOD: October 31, 2024 to Apri ...

Investors looking for stocks in the Medical Services sector might want to consider either Organon (OGN) or Medpace (MEDP) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a proven strategy that targets compani ...

PHILADELPHIA, July 21, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) on behalf of purchasers of Organon securities between November 3, 2022 through April 30, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired Organon securities during the Class Period may, no later than JULY 22, 2025, seek to be appointed as a lead plaintiff representa ...

NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lea ...

集体诉讼案件 - 罗森律师事务所提醒在2022年11月3日至2025年4月30日期间购买Organon证券的投资者注意2025年7月22日的首席原告截止日期 [1] - 投资者可能有权通过应急费用安排获得补偿而无需支付任何自付费用 [1] - 首席原告是代表其他集体成员指导诉讼的代表方 [2] 律师事务所背景 - 罗森律师事务所专注于证券集体诉讼和股东衍生诉讼 在全球范围内代表投资者 [3] - 该事务所曾创下针对中国公司的最大证券集体诉讼和解记录 并在2017年因证券集体诉讼和解数量被ISS证券集体诉讼服务评为第一名 [3] - 自2013年以来每年排名前四 已为投资者追回数亿美元 仅2019年就为投资者获得超过4.38亿美元 [3] 案件细节 - 指控Organon在2022年11月3日至2025年4月30日期间做出虚假和/或误导性陈述 [4] - 公司未披露Nexplanon面临更高的独占权丧失和价格侵蚀风险 长期销售增长不如预期 可能无法在2025财年末达到10亿美元销售额 也无法获得默克公司10亿美元的里程碑付款 [4] - 公司可能无法维持产生10亿美元自由现金流以支持高额股息 也难以维持4.0倍的债务杠杆率 [4] - 公司可能无法维持当前的企业债务评级 [4] - 公司缺乏合理依据报告其业务指标和财务预测 [4] 参与诉讼方式 - 投资者可通过网站、电话或电子邮件联系罗森律师事务所参与集体诉讼 [2][5] - 投资者可选择自己的律师或保持缺席集体成员身份 [6] - 分享未来潜在赔偿的能力不取决于是否担任首席原告 [6]

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Organon (OGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Organon between November 3, 2022 and April 30, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, July 19, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockhold ...

诉讼案件概述 - 律师事务所Robbins Geller Rudman & Dowd LLP对Organon & Co提起集体诉讼，指控其在2022年11月3日至2025年4月30日期间违反《1934年证券交易法》[1] - 诉讼指控Organon及其高管在Class Period内做出虚假或误导性陈述，未披露关键业务风险[4] 公司业务与指控内容 - Organon专注于通过处方疗法和医疗设备提供健康解决方案[3] - 诉讼指控公司隐瞒Nexplanon产品面临更高独占权丧失和价格侵蚀风险，实际销售增长未达预期，2025财年销售额无法达到10亿美元目标[4] - 公司被指无法实现与默克签订的Nexplanon销售10亿美元里程碑付款，且自由现金流不足以维持高额股息[4] - 公司债务杠杆率可能无法维持在4.0倍水平，企业信用评级面临下调风险[4] 财务事件影响 - 2025年5月1日，Organon宣布第一季度财报时将季度股息从每股28美分大幅削减90%至2美分，年化股息从1.16美元降至8美分[5] - CEO Kevin Ali表示资本配置优先级调整为加速去杠杆，目标在年底前将净杠杆率降至4.0倍以下[5] - 股息削减公告导致公司股价单日暴跌超过27%[5] 律师事务所背景 - Robbins Geller在证券欺诈集体诉讼领域具有丰富经验，过去五年中有四年在ISS证券集体诉讼服务排名中位列第一[8] - 2024年该律所为投资者追回超过25亿美元赔偿，金额超过其后五家律所总和[8] - 曾创下72亿美元的历史最大证券集体诉讼赔偿纪录（安然公司案）[9]